Welcome
Support Centre
23 April 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
A randomised, double-blind, placebo-controlled trial to evaluate the efficacy and tolerability of olanzapine as adjunctive treatment for anorexia nervosa in touth: a pilot study
ISRCTN ISRCTN23032339
DOI 10.1186/ISRCTN23032339
ClinicalTrials.gov identifier
EudraCT number
Public title A randomised, double-blind, placebo-controlled trial to evaluate the efficacy and tolerability of olanzapine as adjunctive treatment for anorexia nervosa in touth: a pilot study
Scientific title
Acronym N/A
Serial number at source N/A
Study hypothesis It is hypothesised that youth who present with a severe eating disorder and are treated with olanzapine will demonstrate reduced disordered eating attitudes and beliefs, and a higher rate of weekly weight gain, as compared to a control group treated with placebo. It is also hypothesised that those patients treated with olanzapine will demonstrate better short-term (14 weeks) and long-term (6 months) clinical outcome as compared to patients treated with placebo. It is also predicted that the physical side-effects of olanzapine will be minor given the relatively lose dose (as compared to treatment for patients with schizophrenia), slow titration, and short-term use of olanzapine. Hospitalised patients on olanzapine may be discharged sooner than those on placebo.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment Canada
Disease/condition/study domain Anorexia Nervosa
Participants - inclusion criteria 1. Must give written informed consent or assent
2. Must be female
3. Must be between age 12 and 17 (younger than 18) at beginning of trial
4. Based on the Diagnostic and Statistical Manual of Mental Disorders (4th Edition – Revised, American Psychiatric Association [APA], 2000) must have fulfilled the criteria for diagnosis of Anorexia Nervosa or Eating Disorder Not Otherwise Specified with a Body Mass Index ≤17
Participants - exclusion criteria 1. Subject has known sensitivity to any of the products to be administered
2. Treatment with any other anti-psychotic medication, mood stabiliser, stimulant
3. Treatment with medication known to interact with olanzapine e.g. fluvoxamine, ciprofloxacin
4. Medical illness such as: diabetes, impaired glucose tolerance, hyperlipidemia, hepatic dysfunction, substance abuse, narrrow angle glaucoma, paralytic ileus, or pancreatitis
5. Subject’s inability to comply with trial requirements including lack of comprehension of English
6. Other unspecified reasons that, in the opinion of the Investigator, make subject unsuitable for enrollment
7. Subject is pregnant or is breast-feeding
8. Laboratory exclusion criteria:
a. Total white cell count <2.5
b. Neutrophil count <1.0
c. Liver function tests (aspartate transaminase (AST)/alanine transaminase (ALT) >2 X normal)
d. Positive pregnancy test
e. Electrocardiogram (EKG) – QTc >440 msec or arrythmia other than sinus bradycardia; conduction abnormalities prolonged QTc or other
Anticipated start date 01/09/2005
Anticipated end date 01/09/2007
Status of trial Completed
Patient information material
Target number of participants 50 subjects; 25 intervention, 25 control
Interventions Olanzapine versus Placebo; Olanzapine will be started at a very low dose and gradually titrated up to a predetermined dose.
Primary outcome measure(s) The change from baseline in the Eating Attitudes Test (EAT-26) score measured at week 12 and average weight gain over the first 12 weeks of treatment will be compared using Student’s t-test (assuming a normal distribution of the measures; otherwise, Wilcoxon Mann Whitney test will be used). If necessary, a linear regression model will be fit to assess treatment effect adjusting for variables thought to influence outcome that could result in imbalance between treatment groups at baseline. Treatment effect and its 95% confidence interval will be generated for each primary outcome.
Secondary outcome measure(s) Although the study is not powered to detect differences in safety, we will nevertheless compare the frequency of adverse events between the two study groups using chi-square or Fisher’s exact test. Change from baseline in the EAT-26 score measured at week 15 and at the end of the maintenance period (week 40) as well as weight gain measured at the same time points will be analysed as for the primary outcomes. Change from baseline in the Computer Assisted Personal Interview (CAPI), Children’s Depression Inventory (CDI), Multidimensional Anxiety Scale for Children (MASC), the Eating Disorder Clinician-Parent Rating Sheet, and Child Behavior Checklist (CBCL) will be calculated for weeks 12 and 40. Assuming a normal distribution for each variable (except for the clinician/parent rating sheet), differences between study groups will be assessed using Student’s t-tests. Wilcoxon Mann-Whitney tests or log-transformation will be performed otherwise. The Eating Disorder Clinician/Parent Rating Sheet score will also be compared using a Wilcoxon Mann-Whitney test. A Poisson regression model will be used to compare the total number of hospital admissions between study groups. Rate of hospitalisation will be calculated for each patient as the total number of days in hospital divided by the total time in days spent in the study. Average rates and 95% confidence intervals will be generated for each study group. Rates will then be compared using a Poisson regression model. In order to avoid multiple testing issues, results will be compared with an alpha value adjusted for the number of tests performed using the Bonferonni criterion.
Sources of funding W. Garfield Weston Foundation (Canada)
Trial website
Publications 2008 protocol in http://www.ncbi.nlm.nih.gov/pubmed/18234120
Contact name Dr  Wendy  Spettigue
  Address Psychiatric Director
Eating Disorder Program
Children's Hospital of Eastern Ontario
401 Smyth Road
  City/town Ottawa
  Zip/Postcode K1H 8L1
  Country Canada
  Email wspettigue@cheo.on.ca
Sponsor Children's Hospital of Eastern Ontario (Canada)
  Address 401 Smyth Road
  City/town Ottawa
  Zip/Postcode K1H 8L1
  Country Canada
  Tel +1 613 737 7600
  Email wspettigue@cheo.on.ca
Date applied 08/06/2005
Last edited 11/09/2009
Date ISRCTN assigned 04/11/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.